Table 1. Clinical and pathological baseline characteristics of PRCC2.
No. | Age (years) | Sex | Prognostic risk group | Stage | Grade | FU (months) | Status | Tumor | Normal | Sample type |
---|---|---|---|---|---|---|---|---|---|---|
1 | 30 | M | NA | 3 | 4 | 95.20 | NED | Kidney* | Kidney | Fresh frozen |
2 | 74 | M | NA | 1 | 3 | 46.83 | NED | Kidney* | Kidney | Fresh frozen |
3 | 82 | M | Intermediate | 4 | 3 | 69.40 | Dead | Kidney* | Kidney | Fresh frozen |
4 | 63 | M | NA | 1 | 3 | 81.17 | NED | Kidney* | Kidney | Fresh frozen |
5 | 51 | M | NA | 1 | 3 | 108.60 | NED | Kidney* | PB | Fresh frozen |
6 | 27 | M | High | 4 | NA | 14.50 | Dead | Bone# | PB | FFPE |
7 | 26 | F | High | 4 | 3 | 35.83 | Dead | Kidney# | PB | FFPE |
*, surgical specimen; #, percutaneous needle biopsy specimen. PRCC2, PRCC type 2; NED, no evidence of disease; PB, peripheral blood; FFPE, formalin fixed paraffin embedded.